Figure 4 :Clinical outcomes of COVID-19 in autoimmune rheumatic
diseases. (A) Hospitalization rates. (B) Mortality. (C) ICU admission
rate.
The ICU admission rate of COVID-19 patients with ARDs was
0.077(95%CI:0.051-0.107)(Figure 4). ICU admission rates of RA, SLE and
CTD, PsA were 0.117(95%CI:0.066-0.168), 0.218(95%CI:0.099-0.361) and
0.054(95%CI:0.028-0.081), 0.046(95%CI:0.007-0.084)(Figure p9). The
mortality due to COVID-19 in ARD patients was
0.073(95%CI:0.046-0.104)(Figure 4). Mortality rates of RA, SLE, CTD and
vasculitis were 0.049(95%CI:0.025-0.079), 0.146(95%CI:0.051-0.241),
0.058(95%CI:0.016-0.120), and 0.224(95%CI:0.179-0.269). The mortality
rates in AS, SSC, and gout were 0.000(95%CI:0.000-0.018),
0.007(95%CI:0.000-0.241), and 0.099(95%CI:-0.138 to 0.336), which were
all not statistically significant(Figure p10). SLE patients had the
highest ICU admission rate, and vasculitis patients had the highest
mortality. In contrast, PsA patients had the lowest ICU admission rate,
and RA patients had the lowest mortality.